Eli Lilly and Company

The American Eli Lilly pharmaceutical corporation and R-Pharm signed an agreement at the SPEIF-2016 for the production of Humulin, Humalog and long-acting insulin analogue in the facilities of the Russian producer.

Under the new agreement Lilly will import the original substance (crystals), and the pharmaceutical form will be produced by R-Pharm, Lilly specified. Beside the human insulins, analogues will also be produced.

The total investments of R-Pharm and Lilly in the production will amount to $100 mln. The companies also discussed the possibility to expand the localization regarding other drugs. 

17 June 2016

On June, 24 an agreement was signed at the BIOInternational Convention (San-Diego, California) between R-Pharm and Eli Lilly. Under the agreement, the whole range of the Humulin insulins, including QuickPen pen injectors, will be produced in the Ortat plant (R-Pharm) in the Kostroma Region. The domestic production will completely satisfy the growing need of the Russian consumers for high quality insulins.

24 June 2014
Kostroma region

Investor profile

Eli Lilly and Company

Indiana, USA

Company's website: https://www.lilly.com

T: +1 3172762000

Public company

Contact: Mr John Lechleiter, Director General

Lilly is a leading innovative pharmaceutical company founded in 1876. The company develops partnership relationships with major scientific organizations around the world which helps it find answers to the most urgent problems of healthcare and satisfy the most urgent medical needs of the people.

The company staff is is over 38,000 employees around the world. The company performs clinical trials in 50 countries of the world, has research laboratories in eight countries and production facilities in 13 countries. The corporation’s products are sold in 125 countries.